Literature DB >> 1126760

Cell-mediated cytotoxicity to human pulmonary neoplasms.

B M Vose, M Moore, G D Jack.   

Abstract

Peripheral blood leukocytes from patients with confirmed pulmonary neoplasia were tested for cytotoxicity against cultured cells derived from lung tumours of various histological types, foetal and normal adult lung tissue and tumours arising in organs other than the lung. Leukocytes from 73 percent of patients were cytotoxic for lung-tumour derived cells compared with age- and sex-matched normal donors, while the frequencies of reactivity against normal adult lung-derived cells and cells from unrelated tumours (e.g. bladder, colon, breast) were 42 percent and 18 percent respectively. Leukocytes from lung cancer patients were also cytotoxic for cells derived from foetal lung but susceptibility to cytolysis was variable, cells from 13- and 14-week embryos revealing greatest reactivity (88 percent). Leukocytes from patients with a variety of tumours of non-pulmonary origin or with non-malignant conditions (including respiratory disorders) were also reactive with lung-tumour-derived target cells but with a lower overall frequency (35 percent) than those from lung-cancer patients. The significance of these cytotoxicity data for the existence of tumour-specific host immunoreactivity in lung neoplasia is discussed.

Entities:  

Mesh:

Year:  1975        PMID: 1126760     DOI: 10.1002/ijc.2910150216

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Cell-mediated anti-embryo cytotoxicity in human pregnancy.

Authors:  T Timonen; E Saksela
Journal:  Clin Exp Immunol       Date:  1976-03       Impact factor: 4.330

2.  Leucocytotoxicity in malignant and non-malignant colonic diseases.

Authors:  B M Vose; M Moore; P F Schofield; I W Dymock
Journal:  Clin Exp Immunol       Date:  1975-12       Impact factor: 4.330

3.  Restricted autologous lymphocytotoxicity in lung neoplasia.

Authors:  B M Vose; F Vánky; M Fopp; E Klein
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.